Molecular and functional analysis of monoclonal antibodies in support of biologics development

doi:10.1007/s13238-017-0447-x

Protein Cell

2018, Vol. 9

Issue (1) : 74-85 https://doi.org/10.1007/s13238-017-0447-x

REVIEW

Molecular and functional analysis of monoclonal antibodies in support of biologics development

Xin Wang¹, Zhiqiang An³, Wenxin Luo^1,², Ningshao Xia^1,², Qinjian Zhao¹(

)

¹. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361105, China
². School of Life Sciences, Xiamen University, Xiamen 361105, China
³. Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA

Download: PDF(1319 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Monoclonal antibody (mAb)-based therapeutics are playing an increasingly important role in the treatment or prevention of many important diseases such as cancers, autoimmune disorders, and infectious diseases. Multidomain mAbs are far more complex than small molecule drugs with intrinsic heterogeneities. The critical quality attributes of a given mAb, including structure, post-translational modifications, and functions at biomolecular and cellular levels, need to be defined and profiled in details during the developmental phases of a biologics. These critical quality attributes, outlined in this review, serve an important database for defining the drug properties during commercial production phase aswell as post licensure life cycle management. Specially, the molecular characterization, functional assessment, and effector function analysis of mAbs, are reviewed with respect to the critical parameters and the methods used for obtaining them. The three groups of analytical methods are three essential and integral facets making up the whole analytical package for a mAb-based drug.Such a package is critically important for thelicensure andthepost-licensure lifecyclemanagement of a therapeutic or prophylactic biologics. In addition, the basic principles on the evaluation of biosimilarmAbs were discussed briefly based on the recommendations by the World Health Organization.

Keywords monoclonal antibody molecular characterization ligand binding assay cell based assay heterogeneity functional assessment

Corresponding Author(s): Qinjian Zhao

Issue Date: 01 March 2018

Cite this article:

Xin Wang,Zhiqiang An,Wenxin Luo, et al. Molecular and functional analysis of monoclonal antibodies in support of biologics development[J]. Protein Cell, 2018, 9(1): 74-85.

URL:

https://academic.hep.com.cn/pac/EN/10.1007/s13238-017-0447-x
https://academic.hep.com.cn/pac/EN/Y2018/V9/I1/74

1	Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V,Schlothauer T, Beck H, Emrich T, Harris RJ (2016) Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals 44:291–305
2	An Z (2010) Monoclonal antibodies – a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319–330
3	Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21–50
4	Azimzadeh A, Van Regenmortel MH (1990) Antibody affinity measurements. J Mol Recognit 3:108–116
5	Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345–352
6	Beck A, Diemer H, Ayoub D, Debaene F, Wagner-Rousset E, Carapito C, Van Dorsselaer A, Sanglier-Cianferani S (2013a) Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trac-Trends Anal Chem 48:81–95
7	Beck A, Wagner-Rousset E,Ayoub D, Van Dorsselaer A, Sanglier-Cianferani S (2013b) Characterization of therapeutic antibodies and related products. Anal Chem 85:715–736
8	Bee C, Abdiche YN, Stone DM, Collier S, Lindquist KC, Pinkerton AC, Pons J, Rajpal A (2012) Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions. PLoS ONE 7:e36261
9	Brinckerhoff CC, Schorr K (2015) Patent watch: Have the biosimilar floodgates been opened in the United States? Nat Rev Drug Discov 14:303–304
10	Brych SR, Gokarn YR, Hultgen H, Stevenson RJ, Rajan R, Matsumura M (2010) Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation. J Pharm Sci 99:764–781
11	Cao L, Wang X, Fang M, Xia N, Zhao Q (2016) Detection of subtle differences in analogous viral capsid proteins by allowing unrestricted specific interaction in solution competition ELISA. J Virol Methods 236:1–4
12	Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F,Surowy T (2014) Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. J Immunol Methods 414:69–81
13	Cohen SL, Price C, Vlasak J (2007) Beta-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage. J Am Chem Soc 129:6976–6977
14	den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W (2011) Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28:920–933
15	Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. MAbs 7:9–14
16	Esterman AL, Katiyar A, Krishnamurthy G (2016) Implementation of USP antibody standard for system suitability in capillary electrophoresis sodium dodecyl sulfate (CE-SDS) for release and stability methods. J Pharm Biomed Anal 128:447–454
17	Fekete S, Gassner AL, Rudaz S, Schappler J, Guillarme D (2013) Analytical strategies for the characterization of therapeutic monoclonal antibodies. Trac Trends Anal Chem 42:74–83
18	Fekete S, Beck A, Veuthey JL, Guillarme D (2014) Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J Pharm Biomed Anal 101:161–173
19	Filtz TM, Vogel WK, Leid M (2014) Regulation of transcription factor activity by interconnected post-translational modifications. Trends Pharmacol Sci 35:76–85
20	Finkler C, Krummen L (2016) Introduction to the application of QbD principles for the development of monoclonal antibodies. Biologicals 44:282–290
21	Gahoual R, Busnel JM, Beck A, Francois YN, Leize-Wagner E (2014) Full antibody primary structure and microvariant characterization in a single injection using transient isotachophoresis and sheathless capillary electrophoresis-tandem mass spectrometry. Anal Chem 86:9074–9081
22	Goldstein G (1987) Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transpl Proc 19:1–6
23	Gopinath SCB, Kumar PKR (2014) Biomolecular discrimination analyses by surface plasmon resonance. Analyst 139:2678–2682
24	Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz Bet al. (2014) Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes. MAbs 6:327–339
25	Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RFet al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063–7070
26	Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325–338
27	Hattori T, Taft JM, Swist KM, Luo H, Witt H, Slattery M, Koide A, Ruthenburg AJ, Krajewski K, Strahl BDet al. (2013) Recombinant antibodies to histone post-translational modifications. Nat Methods 10(10):992–995
28	He Y,Isele C, Hou W,Ruesch M (2011) Rapid analysis of charge variants of monoclonal antibodies with capillary zone electrophoresis in dynamically coated fused-silica capillary. J Sep Sci 34:548–555
29	High K, Meng Y, Washabaugh MW, Zhao Q (2005) Determination of picomolar equilibrium dissociation constants in solution by enzyme-linked immunosorbent assay with fluorescence detection. Anal Biochem 347:159–161
30	Hong JK, Lee SM, Kim KY, Lee GM (2014) Effect of sodium butyrate on the assembly, charge variants, and galactosylation of antibody produced in recombinant Chinese hamster ovary cells. Appl Microbiol Biotechnol 98:5417–5425
31	Huang RY, Chen G (2014) Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry. Anal Bioanal Chem 406:6541–6558
32	Huang CY, Hsieh MC, Zhou Q (2017) Application of tryptophan fluorescence bandwidth-maximum plot in analysis of monoclonal antibody structure. AAPS PharmSciTech 18:838–845
33	Hunt G, Hotaling T, Chen AB (1998) Validation of a capillary isoelectric focusing method for the recombinant monoclonal antibody C2B8. J Chromatogr A 800:355–367
34	Iacob RE, Bou-Assaf GM, Makowski L,Engen JR, Berkowitz SA, Houde D (2013) Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements. J Pharm Sci 102:4315–4329
35	Jefferis R (2009) Glycosylation as a strategy to improve antibodybased therapeutics. Nat Rev Drug Discov 8:226–234
36	Johnson CM (2013) Differential scanning calorimetry as a tool for protein folding and stability. Arch Biochem Biophys 531:100–109
37	Jorgenson JW, Lukacs KD (1983) Capillary zone electrophoresis. Science 222:266–272
38	Joshi V, Shivach T, Yadav N, Rathore AS (2014) Circular dichroism spectroscopy as a tool for monitoring aggregation in monoclonal antibody therapeutics. Anal Chem 86:11606–11613
39	Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ (2014a) Physicochemical characterization of Remsima. MAbs 6:1163–1177
40	Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ (2014b) Physicochemical characterization of Remsima (R). Mabs 6:1163–1177
41	Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PAet al. (2016) Structure and function analysis of an antibody recognizing all influenza a subtypes. Cell 166:596–608
42	Kaneko E, Niwa R (2011) Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs 25:1–11
43	Kelley B (2016) Quality by design risk assessments supporting approved antibody products. MAbs 8:1435–1436
44	Kluters S, Wittkopp F, Johnck M, Frech C (2016) Application of linear pH gradients for the modeling of ion exchange chromatography: separation of monoclonal antibody monomer from aggregates. J Sep Sci 39:663–675
45	Knudsen HL, Fahrner RL, Xu Y, Norling LA, Blank GS (2001) Membrane ion-exchange chromatography for process-scale antibody purification. J Chromatogr A 907:145–154
46	Kotia RB, Raghani AR (2010) Analysis of monoclonal antibody product heterogeneity resulting from alternate cleavage sites of signal peptide. Anal Biochem 399:190–195
47	Krayukhina E, Uchiyama S, Nojima K, Okada Y, Hamaguchi I,Fukui K (2013) Aggregation analysis of pharmaceutical human immunoglobulin preparations using size-exclusion chromatography and analytical ultracentrifugation sedimentation velocity. J Biosci Bioeng 115:104–110
48	Leavy O (2010) Therapeutic antibodies: past, present and future. Nat Rev Immunol 10:297
49	Liu L, Braun LJ, Wang W, Randolph TW, Carpenter JF (2014) Freezing-induced perturbation of tertiary structure of a monoclonal antibody. J Pharm Sci 103:1979–1986
50	Liu J, Eris T, Li C, Cao S, Kuhns S (2016) Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab. BioDrugs 30:321–338
51	Marassi V,Roda B, Zattoni A, Tanase M, Reschiglian P (2014) Hollow fiber flow field-flow fractionation and size-exclusion chromatography with MALS detection: a complementary approach in biopharmaceutical industry. J Chromatogr A 1372C:196–203
52	Michels DA, Tu AW, McElroy W, Voehringer D, Salas-Solano O (2012) Charge heterogeneity of monoclonal antibodies by multiplexed imaged capillary isoelectric focusing immunoassay with chemiluminescence detection. Anal Chem 84:5380–5386
53	Moorkens E, Jonker-Exler C, Huys I, Declerck P, Simoens S, Vulto AG (2016) Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol 7:193
54	Moorthy BS, Schultz SG, Kim SG, Topp EM (2014) Predicting protein aggregation during storage in lyophilized solids using solid state amide hydrogen/deuterium exchange with mass spectrometric analysis (ssHDX-MS). Mol Pharm 11:1869–1879
55	Moritz B, Schnaible V, Kiessig S, Heyne A,Wild M, Finkler C, Christians S, Mueller K, Zhang L, Furuya Ket al. (2015) Evaluation of capillary zone electrophoresis for charge heterogeneity testing of monoclonal antibodies. J Chromatogr B 983– 984:101–110
56	Overdijk MB, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WKet al. (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7:311–321
57	Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185
58	Pathak M, Dutta D, Rathore A (2014) Analytical QbD: development of a native gel electrophoresis method for measurement of monoclonal antibody aggregates. Electrophoresis 35:2163–2171
59	Pavlou AK, Belsey MJ (2005) The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 59:389–396
60	Pike RM (1967) Antibody heterogeneity and serological reactions. Bacteriol Rev 31:157–174
61	Ratanji KD, Derrick JP, Dearman RJ, Kimber I (2014) Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol 11:99–109
62	Roberts CJ (2014a) Protein aggregation and its impact on product quality. Curr Opin Biotechnol 30:211–217
63	Roberts CJ (2014b) Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol 32:372–380
64	Roque AC, Lowe CR, Taipa MA (2004) Antibodies and genetically engineered related molecules: production and purification. Biotechnol Prog 20:639–654
65	Rosati S, Yang Y, Barendregt A, Heck AJ (2014) Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry. Nat Protoc 9:967–976
66	Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8:E501–E507
67	Rustandi RR, Washabaugh MW, Wang Y (2008a) Applications of CE SDS gel in development of biopharmaceutical antibody-based products. Electrophoresis 29:3612–3620
68	Rustandi RR, Washabaugh MW, Wang Y (2008b) Applications of CE SDS gel in development of biopharmaceutical antibody-based products. Electrophoresis 29:3612–3620
69	Salmanowicz BP, Langner M, Franaszek S (2014) Charge-based characterisation of high-molecular-weight glutenin subunits from common wheat by capillary isoelectric focusing. Talanta 129:9–14
70	Schuck P (1997) Reliable determination of binding affinity and kinetics using surface plasmon resonance biosensors. Curr Opin Biotechnol 8:498–502
71	Shimura K (2002) Recent advances in capillary isoelectric focusing: 1997-2001. Electrophoresis 23:3847–3857
72	Shukla AA, Hubbard B, Tressel T, Guhan S, Low D (2007) Downstream processing of monoclonal antibodies–application of platform approaches. J Chromatogr B 848:28–39
73	Singla A, Bansal R, Joshi V, Rathore AS (2016) Aggregation kinetics for IgG1-based monoclonal antibody therapeutics. AAPS J 18:689–702
74	Sirin S, Apgar JR, Bennett EM, Keating AE (2016) AB-Bind: antibody binding mutational database for computational affinity predictions. Protein Sci 25:393–409
75	Smith SL (1996) Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 6:109–119 quiz 120-101
76	Suba D, Urbanyi Z, Salgo A (2015) Capillary isoelectric focusing method development and validation for investigation of recombinant therapeutic monoclonal antibody. J Pharm Biomed Anal 114:53–61
77	Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N (2014) Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One 9:e95787
78	Talebi M, Shellie RA, Hilder EF, Lacher NA, Haddad PR (2014) Semiautomated pH gradient ion-exchange chromatography of monoclonal antibody charge variants. Anal Chem 86:9794–9799
79	Telikepalli SN, Kumru OS, Kalonia C,Esfandiary R, Joshi SB, Middaugh CR, Volkin DB (2014) Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J Pharm Sci 103:796–809
80	Terral G, Beck A, Cianferani S (2016) Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization. J Chromatogr B 1032:79–90
81	Thompson NJ, Rosati S, Heck AJ (2014) Performing native mass spectrometry analysis on therapeutic antibodies. Methods 65:11–17
82	Tous GI, Wei Z, Feng J, Bilbulian S, Bowen S, Smith J,Strouse R, McGeehan P, Casas-Finet J, Schenerman MA (2005) Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains. Anal Chem 77:2675–2682
83	Tsuchida D, Yamazaki K, Akashi S (2016) Comprehensive characterization of relationship between higher-order structure and FcRn binding affinity of stress-exposed monoclonal antibodies. Pharm Res 33:994–1002
84	van der Kant R, Karow-Zwick AR, Van Durme J, Blech M, Gallardo R, Seeliger D, Assfalg K, Baatsen P, Compernolle G, Gils Aet al. (2017) Prediction and reduction of the aggregation of monoclonal antibodies. J Mol Biol 429:1244–1261
85	Vivian JT, Callis PR (2001) Mechanisms of tryptophan fluorescence shifts in proteins. Biophys J 80:2093–2109
86	Wakankar A, Chen Y, Gokarn Y, Jacobson FS (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 3:161–172
87	Wang S, Wu G, Zhang X, Tian Z, Zhang N, Hu T, Dai W, Qian F (2017) Stabilizing two IgG1 monoclonal antibodies by surfactants: Balance between aggregation prevention and structure perturbation. Eur J Pharm Biopharm 114:263–277
88	Wei H, Mo J, Tao L, Russell RJ, Tymiak AA, Chen G, Iacob RE, Engen JR (2014) Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Drug Discov Today 19:95–102
89	Wright A, Morrison SL (1997) Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 15:26–32
90	Yang R, Tang Y, Zhang B, Lu X, Liu A, Zhang YT (2015) High resolution separation of recombinant monoclonal antibodies by size-exclusion ultra-high performance liquid chromatography (SE-UHPLC). J Pharm Biomed Anal 109:52–61
91	Yoo DH (2014) The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev Clin Immunol 10:981–983
92	Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ (2012) Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res 29:236–250
93	Zhang H, Cui W, Gross ML (2014) Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies. FEBS Lett 588:308–317
94	Zhao SS, Chen DDY (2014) Applications of capillary electrophoresis in characterizing recombinant protein therapeutics. Electrophoresis 35:96–108
95	Zhou C, Qi W, Lewis EN, Carpenter JF (2015) Concomitant Raman spectroscopy and dynamic light scattering for characterization of therapeutic proteins at high concentrations. Anal Biochem 472:7–20

[1]	Hui Cheng, Zhaofeng Zheng, Tao Cheng. New paradigms on hematopoietic stem cell differentiation[J]. Protein Cell, 2020, 11(1): 34-44.
[2]	Yali Jiang, Yuanyuan Wang, Pengfei Ma, Dongjie An, Junlong Zhao, Shiqian Liang, Yuchen Ye, Yingying Lu, Peng Zhang, Xiaowei Liu, Hua Han, Hongyan Qin. Myeloid-specific targeting of Notch ameliorates murine renal fibrosis via reduced infiltration and activation of bone marrowderived macrophage[J]. Protein Cell, 2019, 10(3): 196-210.
[3]	Xinhua Wang, Mary Mathieu, Randall J. Brezski. IgG Fc engineering to modulate antibody effector functions[J]. Protein Cell, 2018, 9(1): 63-73.
[4]	Liming Liu. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins[J]. Protein Cell, 2018, 9(1): 15-32.
[5]	Xuyuan Zhang, Pan Yang, Nan Wang, Jialong Zhang, Jingyun Li, Hao Guo, Xiangyun Yin, Zihe Rao, Xiangxi Wang, Liguo Zhang. The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection[J]. Protein Cell, 2017, 8(8): 590-600.
[6]	Yingjiao Xue,Shenda Hou,Hongbin Ji,Xiangkun Han. Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance[J]. Protein Cell, 2017, 8(3): 178-190.
[7]	Hong Shan,Zihao Wang,Fa Zhang,Yong Xiong,Chang-Cheng Yin,Fei Sun. A local-optimization refinement algorithm in single particle analysis for macromolecular complex with multiple rigid modules[J]. Protein Cell, 2016, 07(1): 46-62.
[8]	Weifeng Shi, Yi Shi, Ying Wu, Di Liu, George F. Gao. Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan[J]. Prot Cell, 2013, 4(11): 846-853.

Viewed

Full text

Abstract

Cited

Shared

Discussed